Key Takeaways:
EnGene Therapeutics Inc. (ENGN) saw its stock collapse after reporting interim Phase 2 data for its bladder cancer therapy, detalimogene voraplasmid, that showed a solid initial response but raised significant questions about the treatment’s long-term durability.
“The complete response rate at any time… [is] currently tracking within range of approved products,” enGene President and Chief Executive Officer Ron Cooper said on a company call, but he acknowledged the durability data was “at the lower end” of the company’s expectations.
The data from the pivotal Cohort 1 of the LEGEND trial included 124 evaluable patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. While the drug, detalimogene voraplasmid, achieved a 54% complete response rate at any time, the Kaplan-Meier estimated 12-month complete response rate was only 25%. The median duration of response was 8.7 months. The company also noted a weaker 39% anytime complete response rate in a more recently assessed subgroup of 32 patients, a finding it is still analyzing.
The results sent enGene’s shares down more than 76%, prompting analyst downgrades and shareholder-rights investigations. The core issue is whether the current data package is sufficient to support a Biologics License Application (BLA) filing, a key event investors had anticipated for 2026. Durability of response is a critical metric for regulatory approval and commercial success in this type of cancer.
On the positive side, the therapy’s safety profile remains a strength. Most treatment-related adverse events were mild and localized, with only a 2.4% discontinuation rate. The company plans to continue discussions with the U.S. Food and Drug Administration and will provide longer-term durability data for the full cohort in the second half of the year.
The mixed results create significant uncertainty around the BLA filing timeline and the drug's ultimate commercial potential. Investors will be closely watching for the mature durability data in the second half of the year, which will be a critical determinant for the stock's future.
This article is for informational purposes only and does not constitute investment advice.
